Keywords
COVID-19
Vaccines
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze clinical and therapeutic repercussions in patients with rheumatic diseases facing SARS-CoV-2 co-infection. Bibliographic review: The emergence of SARS-CoV-2 in December 2019 generated an international mobilization of the scientific community in order to elucidate clinical and pharmacological repercussions of COVID-19. In carriers of rheumatic diseases, despite tissue injury related to a state of hyperinflammation in the body triggered by COVID-19, they present a broad spectrum of immune dysfunction, making the severity of this infection highly variable and potentially at greater risk. This condition poses a certain challenge, since severe infections are formally known to be a cause of mortality in several rheumatic conditions. Final considerations: The literature aims to prevent complications and ensure safety for patients with rheumatic diseases, which, despite mostly preliminary and observational data, generally corroborate a favorable outcome although some observations about treatment should be emphasized in addition to its potential risk factors.